Compounded semaglutide dosing: the full titration schedule, week by week

The standard compounded semaglutide titration schedule

Most US-licensed 503A compounding pharmacies and prescribing providers use a titration schedule mirroring the FDA-approved Wegovy® protocol. This schedule was used in the STEP 1 clinical trial (Wilding et al., New England Journal of Medicine, 2021) — the foundational trial that established the safety and efficacy of semaglutide for chronic weight management at the 2.4mg weekly dose.

The schedule is not arbitrary. Each dose step is calibrated to let your body adapt to increased GLP-1 receptor activation before the next escalation. Going faster than this schedule materially increases the likelihood of severe nausea, vomiting, or gastrointestinal side effects. Going slower is sometimes appropriate clinically — but staying below 0.5mg-1mg long-term will under-treat for weight management.

Why titration matters

Semaglutide produces its weight-loss effect by activating GLP-1 receptors in the appetite-regulating regions of the brain and the gut. Activating those receptors abruptly at therapeutic doses overwhelms the system — the body responds with strong nausea, vomiting, and gastrointestinal slowdown. Gradual titration lets the receptors and downstream signaling pathways adapt before they are pushed to therapeutic activation levels.

In the STEP 1 trial, approximately 44% of participants experienced nausea, 30% experienced diarrhea, and 24% experienced vomiting at some point during titration to the 2.4mg dose. The vast majority of these events were mild to moderate and resolved over time. Skipping titration steps or escalating faster than the labeled schedule materially increases the rate and intensity of these effects.

What to do if you cannot tolerate a dose step

It is common for patients to need extended time at a particular dose step (typically 0.5mg or 1mg) because side effects do not resolve within the planned 4 weeks. The clinical response is generally to stay at the current dose for another 2-4 weeks before attempting the next escalation, rather than pushing through severe side effects.

• If nausea or vomiting is severe (multiple episodes per day, difficulty keeping food down, dehydration): contact your provider immediately. Do not continue increasing the dose.
• If side effects are moderate but persistent (some nausea daily but functional): hold at the current dose for another 4 weeks. Often resolves by week 6-8.
• If you have been at a dose for 8+ weeks and side effects are mild but the appetite-suppression effect has stalled: discuss the next dose step with your provider. Some patients need to escalate further to maintain clinical effect.
• Never adjust your own dose without consulting your prescribing provider.

Maintenance dose choices: 1.7mg vs 2.4mg

Not every patient escalates to the maximum 2.4mg dose. The 1.7mg dose is itself a therapeutic dose for many patients, and some prefer to maintain at 1.7mg rather than escalate to 2.4mg if their weight goals are being met. The decision is typically made in consultation with the prescribing provider around weeks 16-20:

• Patients near their goal weight at 1.7mg: often stay at 1.7mg as maintenance, especially if side effects are tolerable
• Patients with significant remaining weight to lose: escalate to 2.4mg for the additional clinical effect
• Patients with strong side effects at 1.7mg: may stay at 1.7mg or step back to 1mg as maintenance

Compounded vs FDA-approved Wegovy®

Brand-name and compounded doses are not interchangeable, and there is no dose conversion between them; your provider determines the right dose based on your history. Compounded semaglutide is not FDA-approved and is not therapeutically equivalent to FDA-approved Wegovy®. Compounded versions are prepared by US-licensed 503A pharmacies under patient-specific prescriptions, not by the FDA-inspected commercial manufacturing process Novo Nordisk uses for Wegovy®.

Differences that may affect clinical experience:

Inactive ingredients: Compounded versions may include different preservatives, buffers, or excipients than branded products. Pharmacies vary in their formulation choices.

Concentration: Compounded vials are sometimes prepared at different concentrations than the standardized Wegovy® pen, which can affect injection volume per dose.

Salt form: Compounded semaglutide may be prepared as semaglutide base, semaglutide sodium, or semaglutide acetate. These differ in molecular weight; your pharmacy or provider should account for this.

The efficacy of compounded semaglutide has not been independently evaluated in clinical trials. The 14.9% mean weight loss figure from STEP 1 specifically refers to FDA-approved Wegovy® 2.4mg weekly over 68 weeks. Individual results vary.

How prescribing works

Cora Health does not prescribe medication. Cora Health connects patients with licensed providers at Wasef Health, PC who evaluate each patient individually and — when clinically appropriate — write a patient-specific prescription with a dose schedule tailored to the patient's health profile, prior GLP-1 history, and side-effect tolerance.

Cora Health's compounded semaglutide is fulfilled by VialsRx (US-licensed 503A) or Hallandale Pharmacy (PCAB-accredited 503A). Both pharmacies are named publicly so patients can verify credentials independently. Cora Health is LegitScript-certified.

Sources

All dosing data from the FDA-approved Wegovy® prescribing information and the STEP 1 trial. Compounded semaglutide is not FDA-approved.

• STEP 1 trial — Wilding et al., New England Journal of Medicine 2021 (FDA-approved Wegovy® 2.4mg, 14.9% mean weight loss at 68 weeks): nejm.org/doi/full/10.1056/NEJMoa2032183
• FDA — Wegovy® prescribing information and full dose-escalation schedule: accessdata.fda.gov
• FDA — Compounding and the FDA: Questions and Answers: fda.gov
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io